Clin Genitourin Cancer: Relationship between prostate cancer morbidity and mortality and family history of prostate cancer

The purpose of this study is to determine the relationship between the family history of prostate cancer in first-degree relatives (FDrs) and the incidence and mortality of prostate cancer!----researchers looked at data sets of unknown men recruited in the prostate, lungs, colorectal and ovarian (PLCO) trialsmen with complete information about a family history of prostate cancer in FDRassessed the effect of family history on prostate cancer morbidity and mortality in the multivariate Cox regression modelsimilarly,, the effect of the number of FDR on prostate cancer and the effect of the minimum age at which FDR is diagnosed on prostate cancer were assessedresults, the current analysis included a total of 74,781 participants, including 5,281 participants with a family history of prostate cancer in FDR and 69,500 participants with no family history of prostate cancer in the FDRa total of 7,450 patients (10.5%) were subsequently diagnosed with prostate cancer in the FDR without a family history of prostate cancerand in patients with a family history of prostate cancer in FDR, a total of 889 prostate cancer patients (16.5%) were subsequently diagnosedthe revised multiple Cox regression model analysis showed that the family history of prostate cancer was associated with a higher rate of prostate cancer diagnosis (risk ratio of 1.590; 95% confidence interval of 1.482-1.705; P.lt;.001)the number of FDRs with prostate cancer inwas proportional to the higher incidence of prostate cancer (HR, 1.529; 95% confidence interval ,CI), 1.439-1.624; P.lt;001)family history of prostate cancer in FDR cannot predict higher prostate cancer mortality rates in the PLCO screening (intervention) group (HR, 0.829; 95% CI, 0.422-1.629; P.587), and cancer mortality in the higher PLCO non-screening (control) group (HR, 1.894; 95% CI, 1.154-3.109; P.0122)the number ofof prostate cancer FDR was not related to the higher prostate cancer mortality rate in the PLCO screening (intervention) arm (HR, 0.956; 95% CI, 0.541-1.691; P- .878), and the higher prostate cancer mortality rate in the PLCO non-screening (control) arm (HR, 1.643; 95% CI, 1.083-2.493; P.02, the results suggest that the family history of prostate cancer is associated with an increased risk of diagnosis of prostate cancer in the overall queue of patients and a higher risk of death from prostate cancer in non-screening sub-queues it is necessary to conduct a forward-looking assessment of the role of screening selected high-risk populations, including those with a long family history